Since 2005, more than 40 new medicines for the treatment of type 2 diabetes have been introduced on the market. These consist of 15 new active substances establishing three new classes of non-insulin products, and several new or modified insulin products and combinations. The approval of these products in Europe is regulated via the centralized procedure at the European Medicines Agency. Demonstration of benefit with regard to improved glucose control remains the principal outcome required from confirmatory studies to demonstrate efficacy. For the majority of these new medicines approved since 2005, cardiovascular outcome trials have now been completed, and have invariably supported the cardiovascular safety of these products. In some of these trials additional important benefits have been observed, for instance, a reduction in major adverse cardiovascular events and improvement of renal outcome. The existing regulatory framework and the continuous adaption of regulatory requirements to emerging developments will continue to guide the approval of new products in the future. 
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| INTRODUCTION
Diabetes mellitus affects about 7% of the population in the European Union (EU) 1 ; its increase in prevalence over recent decades is largely attributable to type 2 diabetes (T2D). Recognizing the importance of this disease, the approval of human medicines containing a new active substance for the treatment of diabetes in the EU was made compulsory by European legislation in 2005 via one single, centralized application procedure at the European Medicines Agency (EMA). One of the advantages of this procedure is that it is based on a single EU-wide assessment and the marketing authorization becomes valid throughout the EU member states. Once pharmaceutical companies submit an authorization application for their product to EMA, the Agency's Committee for Medicinal Products for Human Use (CHMP) carries out a scientific assessment of the application, typically including several review cycles which may not exceed 210 days. The CHMP then gives a recommendation to the European Commission on whether or not to grant a marketing authorization, on average about 1 year after submission of the initial application. Each outcome is described in detail in a European Public Assessment Report (EPAR), available on EMA's website (http:// www.ema.europa.eu). This article provides an overview of the approvals of such medicines via this centralized procedure and highlights current and future regulatory trends in T2D.
| APPROVALS OF GLUCOSE-LOWERING AGENTS BEFORE 2005
Before the EMA's establishment in 1995, only insulins, biguanides, sulphonylureas and alpha-glucosidase inhibitors were authorized as glucose-lowering agents in member states of the EU. Table S1 (see the supporting information for this article) and include insulins and insulin analogues, and, as oral glucose-lowering agents, thiazolidinediones and meglitinides.
| APPROVALS SINCE 2005
Since the centralized application procedure was made compulsory for medicinal products for the treatment of diabetes in 2005, more than 40 new products have been reviewed by EMA and subsequently authorized in the EU (Figure 1 , Table S2 ). These include both monotherapies and an increasing number of fixed dose combinations, either as oral tablets or, more recently, as fixed-ratio combinations of injectable medicines (see section 3.2 on insulins); this trend reflects the need for the combination of several agents when the disease progresses. (CV) outcomes observed with these products are covered later in section 5; comparative reviews of these new classes are beyond the scope of this paper, but are available elsewhere (e.g.
| Non-insulin glucose-lowering agents
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| Insulins
Most of the insulins and insulin analogues currently authorized in the EU were already available before 2005. Fast-acting, mealtime insulin analogues were first authorized in 1996 (insulin lispro), and long-acting, basal insulin analogues in 2000 (insulin glargine) (Table S1 ). All insulin products in the EU are authorized for use in both T1D and T2D.
Recently, a new group of injectable, fixed-dose combinations of long- Another recent development is the approval of higher strength pre-filled pen insulins, exceeding the 100 U/mL strength that was previously in general the only one available in the EU. Both higher strength insulins and fixed-dose combinations containing insulin may present added challenges in terms of potential risks of medication errors, the mitigation of which was addressed in a recent guideline dedicated to this matter. 8 The choice of insulin analogues has been broadened by the EU approval of four biosimilar insulin analogues since 2014 (Figure 1 ). The EMA has issued specific guidance for the development of biosimilar insulins and insulin analogues. 9 While an inhalable insulin was approved in 2006 (Exubera), the product was withdrawn shortly after licensing for commercial reasons ( Figure 1 , Table S2 ), and therefore no insulin with non-parenteral delivery is currently authorized in the EU. Further development of new administration routes, new insulin analogues, and non-insulin peptide agonists of the insulin receptor, is ongoing. 10 (Table S2 ).
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| GENERAL REGULATORY ASPECTS OF APPROVALS FOR MEDICINES FOR DIABETES
In 2002, the EMA published a guideline for the development of medicines for diabetes. The guideline 11 has been revised previously and is currently being revised again to reflect recent developments. Beyond HbA1c as a primary outcome, other outcomes are also of importance to patients, and these may in the future help to further refine the profile of diabetes medicines addressing the needs of patients, for instance, quality of life captured as patient-reported outcomes, or periods of hypoglycaemia, captured by continuous glucose-monitoring. 15 
| CARDIOVASCULAR OUTCOME TRIALS IN TYPE 2 DIABETES
General adaptation to emerging knowledge over time, but in particular concerns over the CV safety profile of rosiglitazone, which had its 
FIGURE 2
Approval of new active substances (non-insulin only) for the treatment of type 2 diabetes marketing authorization suspended 16 and was subsequently withdrawn in the EU, led to a revision of guidance relating to the safety data required for regulatory purposes. 17, 18 Current EU guidance requires comprehensive safety data, including a comprehensive assessment of the CV safety of a new medicine developed for the treatment of diabetes. 19 The guidance explains that CVOTs are not mandatory for such products in the EU but that they can be required.
Nevertheless between the various classes, further studies are needed to unravel these mechanisms and justify more specific claims. Also, unexpected effects in terms of rates of retinopathy complications have been observed, 27 also requiring further studies.
| MODIFICATION OF USE OF APPROVED MEDICINES FOR TYPE 2 DIABETES
All medicines for T2D approved in the EU are constantly monitored with regard to safety. Since 2012, EMA has a committee dedicated to the safety of medicines for human use, the Pharmacovigilance Risk Assessment Committee (PRAC), where all major safety issues are discussed. As an example, this has led to the inclusion of the occurrence of keto-acidosis as a side effect of SGLT-2 inhibitors. All suspected side effects that are reported by patients and healthcare professionals must be entered into EudraVigilance, the EU web-based information system operated by EMA, that collects, manages and analyzes reports of suspected side effects of medicines.
New information can also lead to expansion of use. In a recent important case of regulatory action on metformin, new clinical data, epidemiological studies, clinical guidelines from medical bodies and scientific literature were considered, and led the EMA's scientific committee CHMP to conclude that metformin's permitted use in T2D
should be expanded to patients with moderately reduced renal function (GFR [glomerular filtration rate] = 30-59 mL/min). 31 As an outcome of this referral procedure, the product information of all metformin-containing products for the treatment of T2D in the EU was revised, including clear dosing recommendations and advice on the monitoring of these patients.
